EPIX Big Push Forward - 86% Up IN ONE MONTH
ESSA Pharma, Inc. engages in the development of small molecule drugs for prostate cancer. It focuses on producing drugs which selectively block the amino-terminal domain (NTD) of the androgen receptor (AR), potentially overcoming the known AR-dependent resistance mechanisms of castration-resistant prostate cancer (CRPC), and providing CRPC patients with the potential for increased progression-free and overall survival. The company was founded by Marianne D. Sadar and Raymond J. Andersen on January 6, 2009 and is headquartered in Vancouver, Canada.
SHORT INTEREST
102.77K 08/15/19
P/E Current
-1.08
P/E Ratio (with extraordinary items)
-1.45
Average Recommendation: BUY
Average Target Price: 18.63
SHORT INTEREST
102.77K 08/15/19
P/E Current
-1.08
P/E Ratio (with extraordinary items)
-1.45
Average Recommendation: BUY
Average Target Price: 18.63
免責聲明
這些資訊和出版物並非旨在提供，也不構成TradingView提供或認可的任何形式的財務、投資、交易或其他類型的建議或推薦。請閱讀使用條款以了解更多資訊。
免責聲明
這些資訊和出版物並非旨在提供，也不構成TradingView提供或認可的任何形式的財務、投資、交易或其他類型的建議或推薦。請閱讀使用條款以了解更多資訊。